RESUMEN
Commercially available melatonin was found to contain impurities associated with eosinophilia-myalgia syndrome (EMS). From sample analysis, remarkable differences in impurity profiles between the active ingredient from various suppliers could be found. An industrial process was developed which guarantees a high purity melatonin active ingredient. All potential impurities have been characterized and synthetized for analytical conformity with pharmaceutical regulations. To avoid any side effects from impurities, only high-purity melatonin should be utilized from the laboratory through to commercialization.
Asunto(s)
Melatonina/aislamiento & purificación , Cromatografía Líquida de Alta Presión , Contaminación de Medicamentos , Industria Farmacéutica , Estabilidad de Medicamentos , Síndrome de Eosinofilia-Mialgia/inducido químicamente , Síndrome de Eosinofilia-Mialgia/prevención & control , Humanos , Melatonina/farmacología , Melatonina/toxicidad , SeguridadRESUMEN
The Authors consider the inhibition of acidogenesis in the dental plaque by topical application of fluoride. After an examination of the actions of fluoride on the bacterial component of dental plaque, the Authors come to the conclusion that inhibition of acidogenesis is one of the possible anticaries mechanism of topical fluoride.